In patients with symptomatic deep vein thrombosis and pulmonary embolism undergoing treatment with fondaparinux sodium injection 5 mg (body weight less than 50 kg), 7.5 mg (body weight 50 kg to 100 kg), and 10 mg (body weight greater than 100 kg) once daily, the body-weight-adjusted doses provide similar mean steady-state peaks and minimum plasma concentrations across all body weight categories
Regulatory and safety status: AOD 9604 is currently awaiting FDA review
Specifications Research applications Analytical characterizationMolecular interaction assessmentIn vitro signalingComparative research Store at 20 C
AOD-9604 5 mg Key Specifications Peptide Name: AOD-9604 Peptide Type: Synthetic peptide fragment Derived From: C-terminal region of human growth hormone Quantity: 5mg per vial Form: Lyophilized (freeze-dried) powder Grade: Research grade Packaging: Sterile, sealed vial Common Research Applications AOD-9604 is utilized in non-clinical laboratory research related to: Metabolic pathway modeling Growth hormonerelated signaling research Peptide-receptor interaction studies Molecular stability and degradation analysis Experimental peptide behavior in controlled systems All research use must comply with institutional protocols and applicable regulations
These side effects are typically transient and diminish over time with continued use
These medications, initially developed for managing type 2 diabetes, are now widely recognized for their ability to suppress appetite, regulate blood sugar, and promote significant weight loss